{"id":"https://openalex.org/W2890041342","doi":"https://doi.org/10.1200/jco.2018.36.15_suppl.9512","title":"Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma.","display_name":"Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma.","publication_year":2018,"publication_date":"2018-05-20","ids":{"openalex":"https://openalex.org/W2890041342","doi":"https://doi.org/10.1200/jco.2018.36.15_suppl.9512","mag":"2890041342"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2018.36.15_suppl.9512","doi":"https://doi.org/10.1200/jco.2018.36.15_suppl.9512","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2018.36.15_suppl.9512","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5049546835","display_name":"Yousef Zakharia","orcid":"https://orcid.org/0000-0001-9480-2626","observed_orcids":["https://orcid.org/0000-0001-9480-2626"]},"institutions":[{"id":"https://openalex.org/I2802216851","display_name":"University of Iowa Hospitals and Clinics","ror":"https://ror.org/04g2swc55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I126307644","https://openalex.org/I2802216851","https://openalex.org/I4210142782"]},{"id":"https://openalex.org/I4210142782","display_name":"University of Iowa Health Care","ror":"https://ror.org/0431j1t39","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I126307644","https://openalex.org/I4210142782"]},{"id":"https://openalex.org/I4390039339","display_name":"University of Iowa Holden Comprehensive Cancer Center","ror":"https://ror.org/01jhe7086","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I126307644","https://openalex.org/I4390039339"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yousef Zakharia","raw_affiliation_strings":["University of Iowa Hospitals and Clinics, Holden Comprehensive Cancer Center, Iowa City, IA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Iowa Hospitals and Clinics, Holden Comprehensive Cancer Center, Iowa City, IA;","institution_ids":["https://openalex.org/I2802216851","https://openalex.org/I4210142782","https://openalex.org/I4390039339"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055791669","display_name":"Olivier Rixe","orcid":"https://orcid.org/0009-0005-7660-1739","observed_orcids":["https://orcid.org/0009-0005-7660-1739"]},"institutions":[{"id":"https://openalex.org/I25041050","display_name":"Augusta University","ror":"https://ror.org/012mef835","country_code":"US","type":"education","lineage":["https://openalex.org/I25041050"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Olivier Rixe","raw_affiliation_strings":["GRU Cancer Center, Augusta, GA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GRU Cancer Center, Augusta, GA;","institution_ids":["https://openalex.org/I25041050"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103979688","display_name":"John Harris Ward","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I223532165","display_name":"University of Utah","ror":"https://ror.org/03r0ha626","country_code":"US","type":"education","lineage":["https://openalex.org/I223532165"]},{"id":"https://openalex.org/I2801159745","display_name":"Huntsman Cancer Institute","ror":"https://ror.org/03v7tx966","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801159745","https://openalex.org/I4210148268"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Harris Ward","raw_affiliation_strings":["Huntsman Cancer Inst Univ of Utah, Salt Lake City, UT;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Huntsman Cancer Inst Univ of Utah, Salt Lake City, UT;","institution_ids":["https://openalex.org/I223532165","https://openalex.org/I2801159745"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018176156","display_name":"Joseph J. Drabick","orcid":"https://orcid.org/0000-0002-7630-2721","observed_orcids":["https://orcid.org/0000-0002-7630-2721"]},"institutions":[{"id":"https://openalex.org/I82783531","display_name":"Penn State Milton S. Hershey Medical Center","ror":"https://ror.org/01h22ap11","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I82783531"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph J. Drabick","raw_affiliation_strings":["Penn State Hershey Medical Center, Hershey, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Penn State Hershey Medical Center, Hershey, PA;","institution_ids":["https://openalex.org/I82783531"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084480627","display_name":"Montaser F. Shaheen","orcid":"https://orcid.org/0009-0006-1542-2267","observed_orcids":["https://orcid.org/0009-0006-1542-2267"]},"institutions":[{"id":"https://openalex.org/I4390039284","display_name":"UNM Comprehensive Cancer Center","ror":"https://ror.org/05kx2e072","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I169521973","https://openalex.org/I4390039284"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Montaser F. Shaheen","raw_affiliation_strings":["University of New Mexico Comprehensive Cancer Center, Albuquerque, NM;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of New Mexico Comprehensive Cancer Center, Albuquerque, NM;","institution_ids":["https://openalex.org/I4390039284"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089777560","display_name":"Mohammed M. Milhem","orcid":"https://orcid.org/0000-0003-4663-6824","observed_orcids":["https://orcid.org/0000-0003-4663-6824"]},"institutions":[{"id":"https://openalex.org/I2802216851","display_name":"University of Iowa Hospitals and Clinics","ror":"https://ror.org/04g2swc55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I126307644","https://openalex.org/I2802216851","https://openalex.org/I4210142782"]},{"id":"https://openalex.org/I4210142782","display_name":"University of Iowa Health Care","ror":"https://ror.org/0431j1t39","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I126307644","https://openalex.org/I4210142782"]},{"id":"https://openalex.org/I4390039339","display_name":"University of Iowa Holden Comprehensive Cancer Center","ror":"https://ror.org/01jhe7086","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I126307644","https://openalex.org/I4390039339"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mohammed M. Milhem","raw_affiliation_strings":["University of Iowa Hospitals and Clinics, Holden Comprehensive Cancer Center, Iowa City, IA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Iowa Hospitals and Clinics, Holden Comprehensive Cancer Center, Iowa City, IA;","institution_ids":["https://openalex.org/I2802216851","https://openalex.org/I4210142782","https://openalex.org/I4390039339"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011462362","display_name":"David H. Munn","orcid":"https://orcid.org/0000-0002-7711-2858","observed_orcids":["https://orcid.org/0000-0002-7711-2858"]},"institutions":[{"id":"https://openalex.org/I25041050","display_name":"Augusta University","ror":"https://ror.org/012mef835","country_code":"US","type":"education","lineage":["https://openalex.org/I25041050"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Munn","raw_affiliation_strings":["Georgia Cancer Center, Augusta University, Augusta, GA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Georgia Cancer Center, Augusta University, Augusta, GA;","institution_ids":["https://openalex.org/I25041050"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075592761","display_name":"Eugene Paul Kennedy","orcid":"https://orcid.org/0009-0008-7418-3774","observed_orcids":["https://orcid.org/0009-0008-7418-3774"]},"institutions":[{"id":"https://openalex.org/I4210127016","display_name":"NewLink Genetics (United States)","ror":"https://ror.org/03spep839","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127016"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eugene Paul Kennedy","raw_affiliation_strings":["NewLink Genetics Corporation, Ames, IA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NewLink Genetics Corporation, Ames, IA;","institution_ids":["https://openalex.org/I4210127016"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070688456","display_name":"Nicholas N. Vahanian","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127016","display_name":"NewLink Genetics (United States)","ror":"https://ror.org/03spep839","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127016"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nicholas N. Vahanian","raw_affiliation_strings":["NewLink Genetics Corporation, Ames, IA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NewLink Genetics Corporation, Ames, IA;","institution_ids":["https://openalex.org/I4210127016"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112243123","display_name":"Charles J. Link","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127016","display_name":"NewLink Genetics (United States)","ror":"https://ror.org/03spep839","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127016"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Charles J. Link","raw_affiliation_strings":["NewLink Genetics Corporation, Ames, IA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NewLink Genetics Corporation, Ames, IA;","institution_ids":["https://openalex.org/I4210127016"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5006194799","display_name":"Robert R. McWilliams","orcid":"https://orcid.org/0000-0002-8199-5040","observed_orcids":["https://orcid.org/0000-0002-8199-5040"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert R. McWilliams","raw_affiliation_strings":["Mayo Clinic, Rochester, MN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic, Rochester, MN;","institution_ids":["https://openalex.org/I1330342723"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":10,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":41,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"36","issue":"15_suppl","first_page":"9512","last_page":"9512"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.0017999999690800905,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/indoximod","display_name":"indoximod","score":0.9980000257492065},{"id":"https://openalex.org/keywords/indoleamine-2-3-dioxygenase-inhibition","display_name":"indoleamine 2,3-dioxygenase inhibition","score":0.8960000276565552},{"id":"https://openalex.org/keywords/advanced-melanoma","display_name":"advanced melanoma","score":0.8259999752044678},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.890999972820282},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.9049999713897705},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.796999990940094},{"id":"https://openalex.org/keywords/pd-l1-expression","display_name":"PD-L1 expression","score":0.7789999842643738},{"id":"https://openalex.org/keywords/overall-response-rate","display_name":"overall response rate","score":0.7009999752044678},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8379999995231628},{"id":"https://openalex.org/keywords/uveal-melanoma","display_name":"uveal melanoma","score":0.9010000228881836},{"id":"https://openalex.org/keywords/cutaneous-melanoma","display_name":"cutaneous melanoma","score":0.628000020980835},{"id":"https://openalex.org/keywords/tumor-immune-microenvironment","display_name":"tumor immune microenvironment","score":0.5680000185966492},{"id":"https://openalex.org/keywords/drug-safety-and-tolerability","display_name":"drug safety and tolerability","score":0.597000002861023},{"id":"https://openalex.org/keywords/tumor-infiltrating-lymphocytes","display_name":"tumor-infiltrating lymphocytes","score":0.5339999794960022},{"id":"https://openalex.org/keywords/tumor-infiltrating-macrophages","display_name":"tumor-infiltrating macrophages","score":0.6230000257492065}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9286010265350342},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.7810066938400269},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.7310566902160645},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.73033607006073},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.6666474938392639},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.596585750579834},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5652755498886108},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5447756052017212},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.49225059151649475},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.48647448420524597},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4785919189453125},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4743574857711792},{"id":"https://openalex.org/C2779984678","wikidata":"https://www.wikidata.org/wiki/Q2145898","display_name":"Response Evaluation Criteria in Solid Tumors","level":4,"score":0.45283931493759155},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3270362615585327},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.32541587948799133},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.2500453293323517},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.1335989236831665},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2018.36.15_suppl.9512","doi":"https://doi.org/10.1200/jco.2018.36.15_suppl.9512","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2018.36.15_suppl.9512","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3167687951","https://openalex.org/W2735921718","https://openalex.org/W2937655275","https://openalex.org/W2521566919","https://openalex.org/W4252294410","https://openalex.org/W2502903836","https://openalex.org/W2602504090","https://openalex.org/W2509007005","https://openalex.org/W2559160791","https://openalex.org/W2603229248"],"abstract_inverted_index":{"9512":[0],"Background:":[1],"The":[2,224,260,268,296],"indoleamine":[3],"2,3-dioxygenase":[4],"(IDO)":[5],"pathway":[6,63],"is":[7,15],"a":[8,56,78,292],"key":[9],"counter-regulatory":[10],"mechanism":[11],"that,":[12],"in":[13,77,159],"cancer,":[14],"exploited":[16],"by":[17],"tumors":[18],"to":[19,89,218,291],"prevent":[20],"and":[21,44,178,207,273,300],"evade":[22],"anti-tumor":[23],"immunity.":[24],"Inhibitors":[25],"of":[26,38,48,55,87,91,108,190,237,256,278,298,305],"the":[27,53,85,185,219,227],"IDO":[28,62],"pathway,":[29],"such":[30],"as":[31,65,94],"indoximod,":[32],"are":[33],"an":[34,45,61,180,303],"increasingly":[35],"validated":[36],"class":[37],"potential":[39,66],"cancer":[40],"therapeutics.":[41],"Pre-clinical":[42],"data":[43,50,320],"increasing":[46],"body":[47],"clinical":[49],"support":[51],"evaluating":[52,84],"combination":[54,269,297],"checkpoint":[57],"inhibitor":[58,64],"(CI)":[59],"with":[60,164,176,235,312],"treatment":[67,182],"for":[68,96,192,226,315],"advanced":[69],"melanoma.":[70,97],"Methods:":[71],"Advanced":[72],"melanoma":[73,173],"patients":[74,156,163,197,213,287],"were":[75,157,174,280],"enrolled":[76,158,290],"single":[79],"arm":[80],"Phase":[81,160],"2":[82],"trial":[83,328],"addition":[86],"indoximod":[88,299],"standard":[90],"care":[92],"CI":[93,101,110,125,248],"approved":[95,109,128],"Prior":[98],"therapy":[99],"excluding":[100],"was":[102,118,133,209,230,244,252,265,270],"allowed.":[103],"Investigators":[104],"administered":[105,119],"their":[106],"choice":[107],"(pembrolizumab":[111],"(P),":[112],"nivolumab":[113],"(N),":[114],"ipilimumab":[115],"(I).":[116],"Indoximod":[117],"continuously":[120],"(1200mg":[121],"po":[122],"BID),":[123],"concurrent":[124],"dosed":[126],"per":[127,149,186],"US":[129],"label.":[130],"Study":[131],"endpoint":[132],"best":[134],"overall":[135],"response":[136,138,143,147],"(overall":[137],"rate":[139],"(ORR)":[140],"=":[141],"complete":[142],"(CR)":[144],"+":[145],"partial":[146],"(PR))":[148],"site":[150],"reported":[151,313],"RECIST":[152],"1.1.":[153],"Results:":[154],"102":[155],"2.":[161],"70":[162,257],"unresectable":[165],"stage":[166],"III":[167],"or":[168,171],"IV":[169],"cutaneous":[170],"mucosal":[172],"treated":[175],"P":[177,316],"had":[179,198],"on":[181],"imaging":[183,222],"meeting":[184],"protocol,":[187],"pre-specified":[188],"definition":[189],"evaluable":[191],"efficacy":[193],"(EE).":[194],"Additionally,":[195],"15":[196],"uveal":[199],"melanoma,":[200],"4":[201,204],"received":[202,205],"I,":[203],"N,":[206],"1":[208],"never":[210],"treated.":[211],"8":[212],"came":[214],"off":[215],"study":[216],"prior":[217],"first":[220],"on-treatment":[221],"study.":[223],"ORR":[225,304,314],"EE":[228,258],"population":[229],"55.7%":[231],"(39/70,":[232],"36":[233],"confirmed)":[234],"CR":[236,307],"18.6%":[238,308],"(13/70,":[239],"all":[240],"confirmed).":[241],"Median":[242],"PFS":[243],"12.4":[245],"months":[246],"(95%":[247],"9.0-NA).":[249],"Archival":[250],"tissue":[251],"available":[253],"from":[254],"41":[255],"patients.":[259],"PD-L1":[261],"staining":[262],"\u2265":[263],"1%":[264],"54%":[266],"(22/41).":[267],"well":[271],"tolerated":[272],"most":[274],"common":[275],"AEs":[276],"regardless":[277],"attribution":[279],"fatigue,":[281],"nausea,":[282],"pruritus.":[283],"An":[284],"additional":[285],"21":[286],"have":[288],"been":[289],"biopsy":[293,322],"cohort.":[294],"Conclusions:":[295],"pembrolizumab":[301],"demonstrates":[302],"55.7%,":[306],"which":[309],"compares":[310],"favorably":[311],"alone":[317],"(33%).":[318],"Updated":[319],"including":[321],"cohort":[323],"will":[324],"be":[325],"presented.":[326],"Clinical":[327],"information:":[329],"NCT02073123.":[330]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":13},{"year":2020,"cited_by_count":8},{"year":2019,"cited_by_count":7},{"year":2018,"cited_by_count":4}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2018-09-27T00:00:00"}